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vious simulation models have shown the Rx-to-OTC switch of
loratadine to be cost-effective. The purpose of this research is to
empirically assess the overall impact of the Rx-to-OTC switch
of loratadine as well as the speciﬁc impact of different pharmacy
beneﬁt structures on prescription drug utilization and cost in a
variety of plan sponsors. METHODS: Data from a national
pharmacy beneﬁt management organization covering 27 million
lives throughout the US were used. The analysis included a com-
parison of the difference in prescription utilization and cost for
the 12-months after a change in prescription beneﬁts for second-
generation antihistamines (SGA) due to OTC loratadine com-
pared to 12-months before for plan sponsors that instituted no
change, moved SGA to the 3rd-tier and restricted SGA beneﬁts
through prior authorization requirement. Change in utilization
and cost of medications for allergic rhinitis (AR), asthma, respi-
ratory infections and all classes combined was examined. Mul-
tivariate regression analysis was used to control for differences
across study groups. RESULTS: There was a substantial decrease
in utilization and cost of all prescription drugs and combinations
of drug classes. AR patients facing restricted prescription bene-
ﬁts for SGA did not appear to increase utilization of other AR
medications or other medications used to treat comorbid condi-
tions such as asthma, sinusitis and otitis media. CONCLU-
SIONS: Utilization and cost decreased substantially for all types
of medications and all pharmacy beneﬁt structures. Future
studies need to examine the impact of the Rx-to-OTC switch of
loratadine and resultant prescription beneﬁt policies on medical
utilization and OTC antihistamine utilization.
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PATIENT PERCEPTIONS REGARDING THE USE OF OVER-
THE-COUNTER CLARITIN
Nair KV, Sullivan P
University of Colorado, Denver, CO, USA
OBJECTIVE: To examine patient perceptions regarding medica-
tion efﬁcacy, safety and cost of using over-the-counter (OTC)
Claritin and its impact on work related productivity.
METHODS: A web-based survey was administered to employ-
ees of a large University via a voluntary-based e-mail list. Survey
items included the choice of medication used by individuals prior
to and following the availability of OTC Claritin, perceptions of
efﬁcacy, symptom control, cost and safety of OTC Claritin as
well perceptions of work related productivity. Bivariate compar-
isons using chi square analysis were used to describe the study
results. RESULTS: Sample consisted of 221 respondents of which
19% were either taking a prescription medication or nasal spray,
other OTC medications, both a prescription and OTC medica-
tion, allergy shots, herbal medications or who were not treating
their allergies prior to the availability of OTC Claritin switched
to OTC Claritin. Older individuals were less likely to switch to
OTC Claritin. Half the individuals who switched from prescrip-
tion medication to OTC Claritin reported having better control
of their allergic rhinitis symptoms (p < 0.05). In total, 88% of
these individuals reported no difference in side effects between
their prescription medication and OTC Claritin, while 82%
reported that OTC Claritin was more expensive than their prior
prescription medication (p < 0.05). However, only 28% of these
individuals reported their allergy symptoms did not interfere at
all with their work while taking OTC Claritin, while 38%
reported that they were only between 60–80% as productive at
work when taking OTC Claritin. CONCLUSIONS: Preliminary
results suggest that the adoption of OTC Claritin may not be as
widespread as anticipated. While patients’ report equal or better
symptom control with OTC Claritin, self reports of work related
productivity do not appear to corroborate these ﬁndings. Further
research is needed to examine the indirect impact of OTC Clar-
itin on presenteism and absenteeism.
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OBJECTIVES: Patients’ willingness to pay (WTP) for intranasal
corticosteroid (INS) products was evaluated. METHODS: One
hundred twenty patients with allergic rhinitis were recruited
from four US allergy/immunology clinics. Participants chose
between hypothetical INSs differing in degree across six attrib-
utes (smell, taste, aftertaste, throat rundown, nose runout, and
feel of spray) and monthly co-pays ($15, $30, and $50). Attrib-
utes were deﬁned in three levels (strong, weak, and none).
Strength of preference was measured as marginal WTP to avoid
higher-degree levels. RESULTS: Patients were willing to pay $11
(95% conﬁdence interval [CI]: $9 to $13) per month to avoid
strong smell over no smell, $12 (95% CI: $10 to $14) to avoid
strong taste over no taste, $20 (95% CI: $18 to $22) to 
avoid strong aftertaste over no aftertaste, $10 (95% CI: $9 to
$12) to avoid excess throat rundown over no throat rundown,
$11 (95% CI: $9 to $13) to avoid excess nose runout over no
nose runout, and $6 (95% CI: $4 to $8) per month to avoid dry
spray over moist spray. When moderate to low levels were com-
pared, aftertaste, throat rundown, and nose runout were still
associated with a signiﬁcant WTP. Income level was not associ-
ated with changes in WTP except for throat rundown. Patients
with an income >$80,000 were willing to pay more to avoid
excess throat rundown than those with an income <$0,000.
CONCLUSIONS: Patients are willing to pay for an INS with
favorable sensory attributes.
ARTHRITIS—Osteoarthritis
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OBJECTIVE: In September, 2004, rofecoxib was withdrawn
from the market due to cardiovascular safety concerns, and con-
cerns have been raised about the cardiovascular safety of other
Cox-2s. This study identiﬁes the characteristics of Cox-2 users
in the six months preceding rofecoxib withdrawal and tracks the
NSAID utilization of this cohort by cardiovascular risk and other
characteristics. METHODS: Pharmacy claims from a large,
private pharmacy beneﬁt management ﬁrm were analyzed. Indi-
viduals with a claim for any Cox-2 inhibitor in the 180 days
prior to rofecoxib withdrawal were identiﬁed, and their cardio-
vascular risk assessed on a surrogate measure based on pharmacy
claims. Subsequent NSAID utilization of this cohort was tracked
through December, 2004 and through mid-2005. RESULTS:
Over 130,000 Cox-2 users were identiﬁed in the six months prior
to rofecoxib withdrawal. Thirty-four percent were male, 31%
age 65 or older, and 31% had a pharmaceutical marker sug-
gesting cardiovascular risk. In the three months following rofe-
coxib withdrawal, 50% of Cox-2 users had a claim for an
NSAID (Cox-2 or non-selective NSAID), and individuals with
CV risk were more likely than those at lower risk to have an
NSAID claim (57% vs. 47%, p < 0.0001). Of those with an
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NSAID claim, 78% had a claim for a Cox-2, and individuals
with CV risk were more likely than those at lower risk to have
a Cox-2 claim (81% vs. 77%, p < 0.0001). As of December 31,
2004, 36% of continuing Cox-2 users had a pharmaceutical
marker suggesting signiﬁcant cardiovascular risk. CONCLU-
SION: As of December, 2004, most recent Cox-2 users with
ongoing prescription NSAID use continued using Cox-2s rather
than switching to nsNSAIDs, and individuals with cardiovascu-
lar risk were more likely than those at lower risk to continue
Cox-2 use. Subsequent analyses will continue to track utilization
in this cohort of recent Cox-2 users.
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OBJECTIVES: To compare the prescribing trends of traditional
and COX-2 selective NSAIDs by different physician specialties.
We also contrasted the appropriateness of NSAID medication
use between physician specialties by comparing prescribing data
to a clinically accepted therapeutic guideline on the appropriate
use of these medications. METHODS: We conducted a retro-
spective cohort study using pharmacy claims and clinical data on
43,936 adult patients enrolled with an IPA of a midwestern Uni-
versity-associated managed care plan. We identiﬁed continuously
enrolled managed care members who ﬁlled a new prescription
for NSAID or NSAID combination from 1999–2002 on a
chronic-use basis. RESULTS: In total, 1576 patients were started
on a traditional NSAID or a COX-2 inhibitor. Primary care
patients were younger and less likely to have comorbid condi-
tions. Overall, COX-2 use was two times greater among patients
seen by specialists compared to patients seen by PCPs. Use and
appropriateness patterns between the specialties were similar
over the time course of the analysis. Multivariate logistic regres-
sion showed that history of rheumatoid arthritis, osteoarthritis,
generalized musculoskeletal pain, or a serious gastrointestinal
complication were associated with increased likelihood of being
prescribed a COX-2 inhibitor and being placed on therapy con-
sidered inappropriate. History of coronary artery disease and
patient age were associated with an increased risk of receiving
inappropriate therapy. CONCLUSION: In addition to prescrib-
ing COX-2 inhibitors at twice the rate of PCPs, specialists were
less compliant with appropriate use guidelines that considered
comorbidities. Overall compliance with appropriate use guide-
lines was 62%, with PCPs 67% and specialists 49%. Using this
drug class as a model for physician adoption of new therapeutic
agents, specialists were observed to be more likely to use new
drugs, despite the lack of clinical scenarios supporting their 
use over traditional therapies. Education and interventions to
promote appropriate prescribing should target both PCPs and
specialists.
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OBJECTIVES: Several checklists have been proposed for assess-
ing the methodological quality of economic evaluations.
However, there is limited literature on the use of such checklists.
The purpose of this study was to assess the feasibility and relia-
bility of a well-known checklist as a quality assessment tool.
METHODS: Five experienced health economists applied the
BMJ checklist, a 35-item questionnaire, to 12 model-based eco-
nomic evaluations of cyclooxygenase-2 (COX-2) inhibitors.
Overall quality of the studies was assessed by measuring the
number of positive answers to the questions. RESULTS: The ﬁve
assessors were able to apply the checklist to all 12 studies. The
checklist was able to discriminate among the 12 studies, with the
total number of positive answers per study ranging from 87 to
132. Although there was a high level of agreement among the
assessors’ overall scores for the 12 studies, there was consider-
able disagreement on speciﬁc questions, with 100% agreement
among all 5 assessors in only 168/420 (35 ¥ 12) possible
instances. Often, disagreements occurred for seemingly factual
questions (example: Are details of currency or price adjustments
for inﬂation or currency conversion given?). Also, there was a
strong relationship between the overall study quality score of the
studies and the level of agreement among the assessors. This
reﬂected the fact that quality of study reporting is the main focus
of the BMJ checklist, rather than the underlying methodological
quality of the studies. Even given this focus, it was felt that addi-
tional questions related to drug dosing and cost as well as main
model parameters should be added to the checklist. CONCLU-
SIONS: The checklist could discriminate among studies, but
focussed mainly on the quality of reporting rather than the
methodological quality of studies. More study is required of the
purpose, feasibility, and reliability of the various methodological
checklists.
ARTHRITIS—Other
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OBJECTIVE: To characterize the burden of illness of ﬁbromyal-
gia to employers, insurers, and society. METHODS: Two data-
bases were searched, Medline and Healthstar, limited to English
language and years 1990–2004. Key search words included
ﬁbromyalgia, cost, economics, employment, productivity and
disability. Articles were selected that reported utilization of
health care resources characterized by either indirect or direct
costs. The total cost of ﬁbromyalgia and contributing cost 
drivers were determined; costs were compared to other diseases.
RESULTS: A total of 12 articles were reviewed for cost and 
ﬁve of these reported productivity cost. The estimated annual
total cost per patient was $5163–$11,548 for employers,
$2274–$9374 for insurers and $3534.84 for society. Direct costs
included: inpatient, outpatient, ofﬁce visits, medications, alter-
native medicine, diagnostic tests, lab work and emergency room
visits. Indirect costs included: absenteeism, presenteeism, work
loss and disability. Productivity loss, medical care and prescrip-
tions were the major determinants of costs to employers. Insurer
costs were driven by inpatient care, medications and outpatient
visits. Societal costs were driven by health care procedures and
productivity impairments. Productivity costs were accountable
for 26%–54% of the total cost to employers, and were most
often measured by disability and time off work. Only one
abstract was identiﬁed that measured productivity in FMS
patients using a patient-reported measure. CONCLUSION:
Fibromyalgia is a costly condition; with cost drivers varying by
payor type. Productivity is a signiﬁcant cost driver that should
be considered to capture the full burden of ﬁbromyalgia to both
the employer and society. Most studies assessing productivity
